Application of pirfenidone in medicine for treating pancreatic diseases

• Main Authors: GUO HONGLEI, LIANG XUESONG, LI ZHAOSHEN, HU LIANGHAO, WANG DAN, WANG LIJUAN
• Format: Patent
• Language: Chinese; English
• Published: 14.03.2023
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention provides an application of pirfenidone in a medicine for treating pancreatic diseases. According to the invention, the mouse model of chronic pancreatitis induced by leifrotin is established. In-vivo experiments show that pirfenidone significantly alleviates pancreatic tissue alveolar atrophy, inflammatory cell infiltration and tissue fibrosis. In-vitro experiments prove that pirfenidone inhibits activation and migration of pancreatic stellate cells and synthesis of extracellular matrixes and promotes apoptosis of the pancreatic stellate cells. The application has the advantage that pirfenidone has a protective effect on pancreatic fibrosis for the first time. The invention provides a new medical application for the prescription medicine pirfenidone, and provides a new clinical treatment means for chronic pancreatitis. 本发明提供了一种吡非尼酮在治疗胰腺疾病的药物中的应用。本发明建立了雨蛙素诱导的慢性胰腺炎小鼠模型。体内实验发现吡非尼酮显著减轻了胰腺组织腺泡萎缩、炎细胞浸润和组织纤维化。体外实验证明吡非尼酮抑制了胰腺星状细胞的活化、迁移和细胞外基质的合成，促进了胰腺星状细胞的凋亡。本发明优点在于：本发明首次发现吡非尼酮对胰腺纤维化具有保护作用。本发明为处方药吡非尼酮提供了